Exploring Three High Growth Tech Stocks in the United States
In This Article:
Over the last 7 days, the market has dropped 4.4%, yet in the last year, it is up 19%, with earnings forecast to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks that align with these trends can be crucial for investors seeking robust opportunities in the United States market.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| TG Therapeutics | 28.39% | 43.54% | ★★★★★★ |
| Super Micro Computer | 20.49% | 27.13% | ★★★★★★ |
| Sarepta Therapeutics | 24.22% | 44.94% | ★★★★★★ |
| Ardelyx | 27.44% | 65.92% | ★★★★★★ |
| Invivyd | 42.91% | 70.39% | ★★★★★★ |
| G1 Therapeutics | 27.57% | 57.75% | ★★★★★★ |
| Ascendis Pharma | 39.71% | 68.43% | ★★★★★★ |
| Travere Therapeutics | 26.72% | 68.41% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Heron Therapeutics
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Heron Therapeutics, Inc. is a commercial-stage biotechnology company dedicated to developing and commercializing therapies that improve medical care, with a market cap of $273 million.
Operations: Heron Therapeutics focuses on developing and commercializing therapeutic products, generating $136.36 million in revenue from its drug delivery systems segment. The company aims to enhance patient care through innovative medical solutions.
Heron Therapeutics has made significant strides in reducing its net loss from $42.06 million to $9.24 million year-over-year, reflecting a 78% improvement. The company's R&D expenses have been pivotal, with a substantial investment of $26.59 million aimed at advancing their pain management solutions like ZYNRELEF?. This product's inclusion in the proposed 2025 Non-Opioid Policy for Pain Relief under Medicare highlights its potential impact on opioid alternatives in surgical settings, potentially driving future revenue growth by 17.4%.
Viant Technology
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Viant Technology Inc. operates as an advertising technology company with a market cap of $636.41 million.
Operations: The company generates revenue primarily through its Internet Information Providers segment, which reported $243.25 million.
Viant Technology has shown notable growth, with second-quarter sales increasing to $65.87 million from $57.22 million a year ago and net income reaching $0.055 million compared to a net loss of $1.06 million previously. The company's R&D expenses, which amounted to 11.6% of revenue, underscore its commitment to innovation, particularly in AI-driven advertising solutions like the upgraded AI Bid Optimizer that improved performance by 100%. Additionally, Viant's recent share repurchase program saw the company buy back 818,138 shares for $8 million between April and August 2024, representing nearly 5% of outstanding shares. Viant's strategic focus on cookieless advertising technology is gaining traction as evidenced by a successful test with Havas Media Network achieving a remarkable 93% unique reach across premium publishers without traditional cookies. This shift addresses growing privacy concerns and positions Viant well in the evolving digital ad landscape where identity resolution is crucial for advertisers seeking scalable solutions post-cookie era.